Overview 

Castleman disease (MCD), especially in cases linked to HHV-8. While antivirals are crucial for HHV-8-positive individuals, particularly when taken in conjunction with rituximab and antiretroviral therapy, chemotherapy is utilised in cases that are severe or refractory. Although targeted therapies are preferred, this combined approach improves patient outcomes in this complex condition

Introduction

Unusual lymph node growth and systemic symptoms, including fever and exhaustion, are the symptoms of Castleman Disease (CD). 

It is a rare lymphoproliferative illness. There are two main manifestations of the disease: Unicentric Castleman Disease (UCD), which affects a single lymph node region, and multicentric Castleman Disease (MCD), which affects many lymph node locations and results in systemic symptoms. MCD is further divided into three subtypes, each with unique pathogenic causes and clinical characteristics. These include idiopathic MCD (iMCD), human herpesvirus-8-associated MCD (HHV-8-MCD), and POEMS-associated MCD. A precise diagnosis and categorisation are essential for directing therapy choices in light of this heterogeneity.¹ The HHV-8 virus attacks B cells, causing the release of viral interleukin-6 (vIL-6), which in turn stimulates systemic inflammation. This viral cytokine sets HHV-8-MCD apart from other subtypes by causing lymphadenopathy and clinical symptoms.²

In contrast, idiopathic MCD is characterised by an excess of human Interleukin 6 (IL-6) that is not caused by a virus, leading to constitutional symptoms and extensive inflammation. A rare subtype of MCD associated with plasma cell diseases, POEMS-related MCD has distinct clinical symptoms and diagnostic criteria.³ 

Chemotherapy in Castleman Disease

Before the extensive use of biologic treatments, chemotherapy was a significant treatment option for multicentric Castleman Disease. To minimise lymphadenopathy and manage systemic symptoms, conventional chemotherapy regimens including CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) have been employed. These regimes are only used for severe or refractory cases, though, because they frequently have serious toxicities, such as immunosuppression and infection risk.¹

Although they are limited by toxicity and frequently do not have long-lasting effects, alkylating drugs like melphalan have also been used in situations of frequent or refractory illness.² Furthermore, as stated, the cytokine dysregulation at the site of the illness is not immediately addressed by chemotherapy, which helps to explain why many patients see partial and frequently temporary responses.³ Nevertheless, chemotherapy is still a good choice for individuals with severe illness who need quick symptom management or in situations where biologics are not available or are not recommended.¹ While awaiting the effects of biologics, some physicians employ chemotherapy as a bridging treatment.³

Rituximab and immunochemotherapy in HHV-8-Associated MCD

In HHV-8-associated MCD, rituximab, a monoclonal antibody that targets CD20 on B cells, has greatly improved results, particularly in individuals with HIV. Rituximab lowers disease activity and systemic symptoms by reducing B cells, which are databases for HHV-8 infection and producers of inflammatory cytokines (such as viral IL-6). When rituximab monotherapy is used in conjunction with antiretroviral treatment, clinical studies show remission rates of over 90%. As a result of its effectiveness and safety, rituximab is now the recommended first-line medication in several treatment protocols. 

The management of HHV-8-MCD has changed significantly since its inception, particularly for patients who are also HIV-positive, as earlier treatments were less effective and more hazardous.¹ Rituximab is occasionally used in combination with chemotherapeutic drugs such as liposomal doxorubicin or etoposide to improve efficacy in aggressive or resistant cases; nevertheless, this combination raises the possibility of haematologic damage.

 Combination treatments are usually saved for patients who exhibit fulminant symptoms that need immediate control or who do not respond to monotherapy. Chemotherapy aids in cytoreduction in these patients, but physicians must balance the advantages against heightened risks of cytopenias, opportunistic infections, and treatment load.³ Maintenance of patients with persistent or recurrent illness has demonstrated that rituximab therapy prolongs remission. 

According to certain research, individuals with a history of relapse may benefit from periodic rituximab re-administration, which can postpone additional illness flare-ups and lower long-term morbidity. However, there are no established maintenance plans, and choices are frequently made based on viral activity and symptom recurrence.⁵ Rituximab is favoured over conventional chemotherapy because of its generally good safety profile, but infection risk is still a significant issue that needs careful attention.⁴

Antiviral therapy in HHV-8-positive Castleman Disease

Because antiviral medication targets the viral component of the disease, it helps manage HHV-8-associated MCD. Inhibiting HHV-8 replication and lowering viral load, medications including ganciclovir, valganciclovir, and foscarnet can lower the generation of viral cytokines that fuel systemic inflammation. Antiviral therapy is frequently utilized as an adjuvant, particularly in patients with high HHV-8 viremia or those who relapse despite immunotherapy, even though it seldom results in remission on its own. Antivirals are sometimes started in conjunction with immunotherapy to avoid flare-ups or used as a preventative measure during times of high viral activity. Clinical PCR monitoring of the HHV-8 viral load is essential for determining the effectiveness of treatment and directing choices for the start or termination of antiviral therapy.² 

For HIV-positive patients, highly active antiretroviral treatment (HAART) is crucial because it boosts immunity and lowers HHV-8-driven disease activity. However, immune reconstitution inflammatory syndrome (IRIS), which can temporarily intensify MCD symptoms and necessitate cautious therapeutic management, can be brought on by starting HAART. Within weeks of starting HAART, patients may have fevers or increasing lymphadenopathy due to a rapid immunological recovery; corticosteroids are occasionally used to treat these symptoms. Despite this, HAART is still crucial for disease control since it enhances immunological surveillance and suppresses viruses.¹ According to Chan et al.(2016), by treating viral replication and immunological dysregulation at the same time, the combination of antivirals, HAART, and rituximab has significantly increased survival and disease control in recent years. When all three are started promptly and in concert, clinical results are at their best, especially for individuals with high-risk characteristics, including a high HHV-8 viral load and a low CD4 count. In HIV-positive people with MCD, this strategy has also enhanced long-term survival and decreased hospitalisation rates.⁵

Integrated therapy approaches and tailored management

A customised strategy based on the patient's characteristics, viral status, and illness subtype is necessary for the treatment of Castleman disease. The combination of rituximab, antiviral treatment, and HAART has emerged as the most effective form of care for HHV-8-associated MCD, successfully addressing the disease's primary causes.¹ IL-6 inhibitors, such as siltuximab and tocilizumab, which block the inflammatory cytokines that cause symptoms, usually work well for idiopathic MCD. Chemotherapy is still a viable choice as salvage therapy or as a stopgap measure until more focused treatments are administered when patients do not respond well to biologics or exhibit life-threatening symptoms.³ Although corticosteroids can be used to temporarily alleviate symptoms during acute flares, their adverse effects and recurrence risk make them unsuitable for long-term use. In order to maximise results and control problems, hematologists, infectious disease specialists, immunologists, and supportive care teams frequently need to collaborate across academic boundaries.² To be able to guide therapy changes and identify early relapse, treatment plans are customised by tracking clinical response, lymph node status, inflammatory markers, and viral load.⁴ Customised strategy enhances patients' quality of life, reduce toxicity, and maximises efficacy.²

Summary

Chemotherapy and antiviral treatments are still essential for treating Castleman Disease, particularly in instances that are resistant to biologic drugs and MCD linked to HHV-8. Even though IL-6 inhibitors have revolutionised the way that idiopathic MCD is treated, chemotherapy is still necessary for cases of the illness that develop quickly or when access to biologics is restricted. 

Targeting both viral infection and immunological dysregulation, the combination of rituximab, HAART, and antivirals has greatly improved prognosis in patients with HHV-8. Patients with resistant or relapsing disease have hope thanks to new therapy approaches like JAK-STAT pathway inhibitors, mTOR inhibitors like sirolimus, and developing immunomodulatory medications. 

Research continues to be conducted to find biomarkers for improved patient stratification, create safer and more effective treatments, and enhance early detection. To enhance outcomes in this uncommon and diverse disease, a customised, integrated treatment strategy involving immunomodulatory, antiviral, and chemotherapeutic medicines is still necessary until these advancements are generally accessible.